Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News JOHNSON & JOHNSON JNJ

Healthcare Biotechnology
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSE:JNJ)

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire December 12, 2024

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

Business Wire December 10, 2024

CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study

PR Newswire December 9, 2024

Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options

PR Newswire December 9, 2024

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma

PR Newswire December 8, 2024

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

PR Newswire December 8, 2024

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma

PR Newswire December 8, 2024

Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)

PR Newswire December 2, 2024

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

PR Newswire November 22, 2024
View More News ››

Opinion & Analysis (NYSE:JNJ)

The ProMIS of an Alzheimer's cure

The Life Sciences Report May 4, 2017

Investment in cell and gene therapies ramps up

The Life Sciences Report June 8, 2016

What Andy Grove and Michael Milken have taught us about prostate cancer

The Life Sciences Report April 20, 2016

Use stock volatility to invest in innovative oncology companies: JMP Security's Michael King Jr.

Gail Dutton October 15, 2015

Bearish On Bucks? Try This ETF

Benzinga.com  September 18, 2015

Eight iconic American companies that have been hurt by the strong dollar

Stockhouse Editorial September 10, 2015
View More Opinion ››

Bullboard Posts (NYSE:JNJ)

Rate cuts are pulling attention toward growth sectors

Hi J&J followers!   Rate cuts are pulling attention toward growth sectors, but what does this mean for healthcare giants...
cmarketinsights - December 10, 2024

JNJ: Strong Pharma Growth, But Legal Risks Remain ⚠️

JNJ’s pharma division is crushing it, with big hits like Imbruvica and Darzalex driving revenue. But the ongoing legal battles—especially...
SmartBull65 - December 3, 2024

$JNJ Steady but Slow: Where’s the Spark?

Johnson & Johnson ($JNJ) is a safe, steady name but lacks growth oomph. Diagnostic biotech firms, like MYNZ, bring the innovation...
WealthLine48 - November 26, 2024

JNJ's Flatline: Buy Opportunity?

I’ve been watching JNJ, and despite its steady dividends, the stock is stuck around $155. Promising drug trials like their psoriasis...
SmartBull65 - November 24, 2024

Is $JNJ Ready to Bounce Back?

Just checked the chart on $JNJ—looks like it’s been consolidating for a minute. Could see a reversal soon if support holds at $152. Also...
TradeDriver718 - November 22, 2024

Johnson & Johnson Announces Quarterly Dividend for Third Qua

Just In: $JNJ Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024Johnson @ Johnson (NYSE: JNJ) today announced...
whytestocks - July 17, 2024
View more Bullboard ››

Biosenta Inc.

Biosenta Inc.

Biosenta Inc. is engaged in developing, producing, and manufacturing an array of chemical compounds for household and ...
View More »